30532-37-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(4'-Piperidinyl) pyridine is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be incorporated into molecules with potential therapeutic effects, making it a valuable component in drug development.
Used in the Development of Neurological Treatments:
In the field of neurology, 2-(4'-Piperidinyl) pyridine is utilized as a building block for the development of new drugs aimed at treating neurological disorders such as Alzheimer's disease and Parkinson's disease. Its incorporation into drug molecules can potentially enhance their efficacy in managing these conditions.
Used in Coordination Chemistry:
2-(4'-Piperidinyl) pyridine also serves as a ligand in coordination chemistry, where it forms complexes with metal ions. These complexes have potential applications in various fields, including catalysis, materials science, and as models for understanding biological systems.
Used in the Synthesis of Heterocyclic Compounds:
Furthermore, 2-(4'-Piperidinyl) pyridine is employed in the synthesis of heterocyclic compounds, which are important in organic chemistry and have a wide range of applications, from pharmaceuticals to agrochemicals and dyes. Its ability to form heterocyclic rings contributes to the creation of novel compounds with diverse properties and potential applications.

Upstream product

• 102325-51-9 2-(4'-pyridinyl)pyridine N'-oxide 
• 50461-51-3 4-(pyridin-2-yl)-1,2,3,6-tetrahydropyridine 
• 143924-45-2 1',2',3',4',5',6'-hexahydro-2'H-[2,4'-bipyridine] dihydrochloride 
• 1121-89-7 piperidine-2,6-dione 
• 7732-18-5 water 
• 206446-49-3 3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-carboxylic acid tert-butyl ester 
• 161610-17-9 1-benzyloxycarbonyl-4-(pyridin-2-yl)-1,2,3,6-tetrahydropyridine 
• 581-47-5 4-(2-pyridyl)pyridine 
• 90606-77-2 3',6'-dihydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 161609-68-3 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(pyridin-2-yl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 1049095-62-6 1-[5-(Methylsulfonyl)-3-{3-[(2-piperidin-1-ylethyl)sulfanyl]-4-(trifluoromethyl)phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(4-pyridin-2-ylpiperidin-1-yl)propan-2-ol 
• 1544656-88-3 2-(1-((6-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)piperidin-4-yl)pyridine 
• 630116-49-3 N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide 
• 1197901-66-8 (2R,3R)-2-(2,4-difluorophenyl)-3-(4-pyridin-2-ylpiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol 
• 877678-70-1 N-[2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]-4-pyridin-2-ylpiperidine-1-carbothioamide 

Relevant academic research and scientific papers

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

PHARMACEUTICAL CONSISTING OF CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof exhibiting effects on dopamine D4 receptor with high selectivity and useful as a treatment agent of central nervous system diseases such as attention deficit hyperkinesis disorder. SOLUTION: There is provide a compound represented by the formula (1) and a pharmaceutically acceptable salt thereof. (1), where n and m are each independently 1 or 2, Ra is a C1-6 alkyl group, a C3-6 cycloalkyl group or an amino group, Rb is H, a C1-6 alkyl group or an alkyl group-substituted/unsubstituted amino group, Rb is H when Ra is the amino group, Rc1 and Rc2 are each independently H or a C1-6 alkyl group, Rd1 and Rd2 are each independently H, F or a C1-6 alkyl group, a ring Q is substituted/unsubstituted 5- to 10-membered nitrogen-containing heteroaryl group and bond containing break lines is a single bond or a double bond. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D 2 and α1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]- 1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.

TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein R represents H, C1-6 alkyl, SO2R1, SO2NR1R2, or COR1; R1 and R2 independently represent C1-6alkyl; and Ring A represents a phenyl ring or a pyridinyl ring; may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein L is C1-4 alkyl;RA, RB, RC, RD, and RE, are as described in the specification;Z is selected from the group consisting of N, C and CH; andA is aryl and heteroaryl as described in the specification.

Oximes and hydrazones that are useful in treating sexual dysfunction

The present invention relates to oximes and hydrazones of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Benzimidazoles that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction

A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D 4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin- 1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D 4 selective agonism in this series of analogues.

BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.